PTCT

TherapeuticsNasdaqGS:PTCT Stock Report

Market Cap

US$3.0b

7D

2.0%

1Y

-9.7%

Updated

18 Sep, 2021

Data

Company Financials +
PTCT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance0/6
Financial Health2/6
Dividends0/6

PTCT Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.

Price History & Performance

Summary of all time highs, changes and price drops for Therapeutics
Historical stock prices
Current Share PriceUS$42.63
52 Week HighUS$36.38
52 Week LowUS$70.82
Beta1.07
1 Month Change12.72%
3 Month Change-4.50%
1 Year Change-9.72%
3 Year Change-5.56%
5 Year Change265.61%
Change since IPO158.52%

Recent News & Updates

Sep 09
Estimating The Intrinsic Value Of PTC Therapeutics, Inc. (NASDAQ:PTCT)

Estimating The Intrinsic Value Of PTC Therapeutics, Inc. (NASDAQ:PTCT)

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of PTC Therapeutics, Inc...

Shareholder Returns

PTCTUS BiotechsUS Market
7D2.0%0.3%-0.6%
1Y-9.7%25.7%33.8%

Return vs Industry: PTCT underperformed the US Biotechs industry which returned 25.7% over the past year.

Return vs Market: PTCT underperformed the US Market which returned 33.6% over the past year.

Price Volatility

Is PTCT's price volatile compared to industry and market?
PTCT volatility
PTCT Beta1.07
Industry Beta1.03
Market Beta1

Stable Share Price: PTCT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: PTCT's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998963Stuart Peltzhttps://www.ptcbio.com

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil.

Valuation

Is Therapeutics undervalued compared to its fair value and its price relative to the market?

15.31x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: PTCT ($42.63) is trading above our estimate of fair value ($39.42)

Significantly Below Fair Value: PTCT is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PTCT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: PTCT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PTCT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PTCT is overvalued based on its PB Ratio (15.3x) compared to the US Biotechs industry average (3.2x).


Future Growth

How is Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

68.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PTCT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: PTCT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PTCT's is expected to become profitable in the next 3 years.

Revenue vs Market: PTCT's revenue (20.1% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: PTCT's revenue (20.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PTCT's Return on Equity is forecast to be very high in 3 years time (205.7%).


Past Performance

How has Therapeutics performed over the past 5 years?

-32.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PTCT is currently unprofitable.

Growing Profit Margin: PTCT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PTCT is unprofitable, and losses have increased over the past 5 years at a rate of 32.8% per year.

Accelerating Growth: Unable to compare PTCT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: PTCT has a negative Return on Equity (-198.93%), as it is currently unprofitable.


Financial Health

How is Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: PTCT's short term assets ($1.1B) exceed its short term liabilities ($291.0M).

Long Term Liabilities: PTCT's short term assets ($1.1B) do not cover its long term liabilities ($1.6B).


Debt to Equity History and Analysis

Debt Level: PTCT's debt to equity ratio (219%) is considered high.

Reducing Debt: PTCT's debt to equity ratio has increased from 57.4% to 219% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PTCT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PTCT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PTCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PTCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PTCT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTCT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PTCT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Stuart Peltz (61 yo)

23.67yrs

Tenure

US$10,552,792

Compensation

Dr. Stuart W. Peltz, Ph D., co-founded PTC Therapeutics Inc. in 1998 and has been its Chief Executive Officer since 1998. Dr. Peltz has been Independent Director of Health Sciences Acquisitions Corporation...


CEO Compensation Analysis

Compensation vs Market: Stuart's total compensation ($USD10.55M) is above average for companies of similar size in the US market ($USD5.28M).

Compensation vs Earnings: Stuart's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PTCT's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: PTCT's board of directors are seasoned and experienced ( 15.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PTCT insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.3%.


Top Shareholders

Company Information

PTC Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: PTC Therapeutics, Inc.
  • Ticker: PTCT
  • Exchange: NasdaqGS
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.010b
  • Shares outstanding: 70.60m
  • Website: https://www.ptcbio.com

Number of Employees


Location

  • PTC Therapeutics, Inc.
  • 100 Corporate Court
  • South Plainfield
  • New Jersey
  • 7080
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 00:49
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.